Ernexa Therapeutics Inc. ERNA
2.02 USD +0.07 (+3.59%)
At closeNov 3, 2026, 4:02 PM EST
2.02 0.00 0.00%
After hours · Nov 3, 4:02 PM ET
1.99 Day range 2.12
1.84 52-week range 47.25
- YTD
- -93.27%
- 1 year
- -95.16%
- Market cap
- 3.30M
- Revenue (ttm)
- 162.00K
- EPS (ttm)
- -13.63
- Shares out
- 51.37M
- Forward P/E
- -0.03
- YTD return
- -93.27%
- 1-year return
- -95.16%
- Volume
- 11.36K
- Avg volume
- 49.79K
- Open
- 2.08
- Previous close
- 1.95
- Day's range
- 1.99 – 2.12
- 52-week range
- 1.84 – 47.25
- Beta
- 7.77
2Y -399.20 (-99.49%)
Key statistics
- Enterprise value
- 51.71M
- PEG ratio
- 0.00
- Price / sales
- 77.82
- Price / book
- 0.59
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.78M
- Total cash
- 2.59M
- Total debt
- 49.20M
- Return on equity
- 0.00%
- Short % of float
- 0.09%
- 50-day average
- 0.7302
- 200-day average
- 1.58
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
ERNA Revenue — quarterly 0
ERNA Net income — quarterly -4.01M
ERNA EPS — quarterly -3.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | -4.92 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | 0.00 | -1.02 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.23 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | -1.14 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -1.03 | — | — |
| Aug 11, 2023 | Jun 1, 2023 | 0.00 | -0.85 | — | — |
About Ernexa Therapeutics Inc.
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- eternatx.com
News
Ernexa Therapeutics Highlights ERNA-101's Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment 
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series 
Ernexa Therapeutic To Present New Preclinical Data From Its ERNA-101 Lead Oncology Program At The Next-Generation Cancer Therapeutics Meeting, October 6–8 
Ernexa Therapeutics' ERNA-101 Selected for Flash Talk Presentation at Nature Conferences' Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic 
Ernexa Therapeutics Announces Encouraging Results From Three Core IND-Enabling Safety Studies Of ERNA-101, Lead Synthetic, Allogeneic iMSC Therapy Engineered To Express IL-7/IL-15 Fusion Cytokine 
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND 
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Your note
Sign in to keep a note on ERNA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHERINGTON CHARLES | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 28, 2024 | 16,628,100 |
| GURROLA SANDRA M | Officer | Conversion of Exercise of derivative security | Jun 20, 2024 | 1,185 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Corient Private Wealth LLC | 0.51% | 262,862 | 64.51K | Sep 29, 2024 |
| Cypress Point Wealth Management, LLC | 0.18% | 94,375 | 23.16K | Sep 29, 2024 |
| UBS Group AG | 0.16% | 83,620 | 20.52K | Sep 29, 2024 |
| Naviter Wealth, LLC | 0.15% | 78,796 | 19.34K | Sep 29, 2024 |
| Sippican Capital Advisors | 0.13% | 68,504 | 16.81K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.06% | 32,860 | 8.06K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.05% | 26,099 | 6.40K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.03% | 13,097 | 3.21K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.01% | 3,129 | 767 | Oct 30, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 8 | 1 | Aug 30, 2024 |
| Fidelity Total Market Index Fund | 0.00% | 2,047 | 502 | Oct 30, 2024 |